Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Joshua S. Boger sold 8,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $82.48, for a total transaction of $659,840.00. Following the completion of the transaction, the director now directly owns 276,225 shares in the company, valued at $22,783,038. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 83.17 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $71.46 and a one year high of $105.50. The stock’s 50 day moving average price is $78.64 and its 200-day moving average price is $87.48. The stock’s market cap is $20.63 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.18 by $0.02. Vertex Pharmaceuticals had a negative net margin of 13.45% and a negative return on equity of 5.31%. The company earned $413.78 million during the quarter, compared to analyst estimates of $423.53 million. During the same quarter last year, the business earned ($0.13) EPS. The company’s revenue for the quarter was up 33.6% compared to the same quarter last year. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post $0.83 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this story can be accessed at http://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-director-sells-659840-00-in-stock/1061152.html.

Institutional investors have recently added to or reduced their stakes in the stock. Shell Asset Management Co. raised its position in Vertex Pharmaceuticals by 28.0% in the second quarter. Shell Asset Management Co. now owns 31,059 shares of the pharmaceutical company’s stock worth $2,672,000 after buying an additional 6,799 shares during the period. Bank of Montreal Can bought a new position in Vertex Pharmaceuticals during the second quarter worth $14,876,000. Rothschild Capital Partners LLC bought a new position in Vertex Pharmaceuticals during the second quarter worth $334,000. Strs Ohio raised its position in Vertex Pharmaceuticals by 9.9% in the second quarter. Strs Ohio now owns 346,339 shares of the pharmaceutical company’s stock worth $29,792,000 after buying an additional 31,241 shares during the period. Finally, Conning Inc. raised its position in Vertex Pharmaceuticals by 0.3% in the second quarter. Conning Inc. now owns 5,740 shares of the pharmaceutical company’s stock worth $494,000 after buying an additional 20 shares during the period. Institutional investors and hedge funds own 95.29% of the company’s stock.

VRTX has been the topic of a number of analyst reports. Jefferies Group reiterated a “buy” rating and issued a $105.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, October 21st. RBC Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 12th. Leerink Swann set a $112.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, September 17th. Credit Suisse Group set a $110.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, September 28th. Finally, Stifel Nicolaus set a $109.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, September 29th. Sixteen equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Vertex Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $105.91.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.